“The effectiveness of novel agents, such as abiraterone acetate (suppresses adrenal androgens ) or enzalutamide (MDV3100, potent AR antagonist), in treating advanced prostate cancer underlines the on‐going critical role of the AR throughout all stages of the disease.”